Fall Allergies: The Pharmacist’s Role in Allergic Rhinitis Symptom Management and Patient Counseling

Thom Kim Nguyen, PharmD, BCPS, CTTS
Published Online: Monday, August 11, 2014
Follow Pharmacy_Times:
Supported by educational grants from Meda Pharmaceuticals, Inc, and Merck Sharp & Dohme Corp.

Fall Allergies: The Pharmacist’s Role in Allergic Rhinitis Symptom Management and Patient Counseling

Thom Kim Nguyen, PharmD, BCPS, CTTS
Clinical Assistant Professor
Ernest Mario School of Pharmacy
Rutgers, The State University of New Jersey
Piscataway, New Jersey
Clinical Coordinator, Ambulatory Care
Hunterdon Medical Center
Flemington, New Jersey

Activity Overview
This activity is intended to provide education to community pharmacists on how to identify triggers of allergic rhinitis, as well as manage and counsel patients who suffer from it during the fall.

EDUCATIONAL OBJECTIVES
After participating in this activity, participants should be able to:
  • Identify potential triggers of allergic rhinitis (AR) in the fall
  • Select management strategies for fall AR, including OTC and prescription pharmacotherapy, immunotherapy, allergen avoidance, and alternative medicine
  • Implement effective counseling techniques to assist with optimal symptom management in patients with AR triggered by fall allergens
Target audience: Pharmacists
Type of activity: Knowledge
Release date: August 8, 2014
Expiration date: August 5, 2016
Estimated time to complete activity: 2.0 hours
Fee: Free

Description: Pharmacy Times/Ascend Media Office of Continuing Professional EducationPharmacy Times Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.2 CEUs) under the ACPE universal activity number 0290-0000-14-063-H01-P. The activity is available for CE credit through August 5, 2016.


Related Articles
Many patients who claim to have penicillin allergies may not actually be allergic to the antibiotic.
Mylan Inc. today announced it has signed a multi-year strategic alliance agreement with Walt Disney Parks and Resorts to help increase awareness of anaphylaxis, a life-threatening allergic reaction. The agreement includes updated maps in Disney's domestic theme parks and on its cruise ships as well as updated signage in the parks that highlight locations with EpiPen® and EpiPen Jr® Auto-Injectors. Over time, the companies also will introduce a variety of educational resources designed to increase awareness of and preparedness for severe allergic reactions.
Allergy & Asthma Network today announced a unique collaboration at the ACAAI’s 2014 Annual Scientific Meeting in Atlanta. Both membership organizations will combine their specialized expertise and skills to help patients manage chronic conditions while updating health care professionals, pharmacies, and government officials about current best practices.
Latest Issues
$auto_registration$